Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement

Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the opening of a new innovation center in Bellevue, Washington, marking the relocation of its previous Seattle-area operations to a dedicated facility designed to support research and development (R&D) while strengthening collaboration and customer engagement. The new site has been renovated to serve as a dedicated hub for innovation and technical excellence. As the sole tenant of the building, Cytek has designed the space to bring together key capabilities under one roof. The facility includes R&D laboratories and dedicated areas for instrument service training and customer demonstrations, along with assembly and testing operations. The Bellevue innovation center reflects Cytek’s strategic investment in an environment that fosters collaboration and accelerates product development. It is designed to enable R&D teams to develop the next generation of technologies. Located in a region known for its concentration of global technology companies, the facility positions Cytek within a dynamic ecosystem that supports ongoing scientific advancements. In addition to its core technical functions, the site incorporates employee-focused amenities and collaborative workspaces intended to encourage creativity, idea exchange, and cross-functional teamwork. The design supports Cytek’s vision of creating an environment where teams can develop and refine new solutions that address evolving needs in research and clinical applications.

“The Bellevue innovation center represents an important step in strengthening our ability to develop and deliver new technologies,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “It highlights our commitment to building the infrastructure needed to advance scientific discovery and enable meaningful innovation.” The opening of the Bellevue facility underscores Cytek’s continued investment in infrastructure that supports its long-term growth and reinforces its efforts to advance high-dimensional cell analysis through innovation, training, and customer support. For more information, please visit https://cytekbio.com/.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP ® ) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Muse ® Micro system; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis ® and Guava ® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe.